The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tisotumab vedotin in head and neck squamous cell carcinoma: Updated analysis from innovaTV 207 Part C.
 
Lova Sun
Consulting or Advisory Role - Bayer; Genmab/Seagen; Genzyme; MJH Life Sciences; Regeneron
Research Funding - Abbvie (Inst); Blueprint Medicines (Inst); Erasca, Inc (Inst); Immunocore (Inst); IO Biotech (Inst); Seagen (Inst)
 
Jerome Fayette
Honoraria - Bristol-Myers Squibb; Hookipa Pharma; Merck Serono; Merck Sharp & Dohme; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Elevar Therapeutics; Hookipa Pharma; ITeos Therapeutics; Merck Serono; Merck Sharp & Dohme; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Sebastien Salas
No Relationships to Disclose
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - 28Bio; Acuta; Adaptimmune; Alkermes; Alphasights; Amgen; AUM Biosciences; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; Bridgebio; COG; Cor2Ed; Cowen; EcoR1 Capital; Exelixis; Experimental Drug Development Centre (EDDC)/A*STAR; Genentech; Gennao Bio; Gerson Lehrman Group; Gilead Sciences; GroupH; Guidepoint Global; HCW Precision; Immunogen; Incyte; Infinity Pharmaceuticals; Inhibrix Inc; Janssen; Jounce Therapeutics; Liberum; MedaCorp; Medscape; Novartis; Numab; Oncologia Brasil; Pfizer; Pharma Intelligence; Precision Oncology Experimental Therapeutics; Prime Oncology; RAIN; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; Turning Point Therapeutics; WebMD; YingLing Pharma; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); F. Hoffmann LaRoche (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Pyramid Biosciences (Inst); Seagen (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Teckro (Inst); Turning Point Therapeutics (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; CLCC; Genmab; Society for Immunotherapy of Cancer; Telperian
 
Douglas Adkins
Consulting or Advisory Role - Boehringer Ingelheim; Calliditas Therapeutics; CUE Biopharma; Eisai Europe; Exelixis; Genmab/Seattle Genetics; Gilead Sciences; Immunitas; Jazz Pharmaceuticals; Kura Oncology; Merck; Seagen; TargImmune Therapeutics; Vaccinex
Research Funding - Adlai Nortye (Inst); AstraZeneca (Inst); BeiGene (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calliditas Therapeutics (Inst); Celgene (Inst); Cofactor Genomics (Inst); CUE Biopharma (Inst); Debiopharm Group (Inst); Epizyme (Inst); Genmab (Inst); Gilead Sciences (Inst); Hookipa Biotech (Inst); Immutep (Inst); ISA Pharmaceuticals (Inst); Kura Oncology (Inst); Lilly (Inst); Merck (Inst); NATCO Pharma (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Vaccinex (Inst)
 
Lara Dunn
Consulting or Advisory Role - Merck
Research Funding - CUE Biopharma; Nektar; Regeneron; Replimune; Seagan; Seagan
 
Fortunato Ciardiello
Consulting or Advisory Role - Amgen; Bayer; Merck KGaA; Pfizer; Roche/Genentech
Research Funding - Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Roche/Genentech (Inst); SERVIER (Inst); Symphogen (Inst)
 
Beatriz Cirauqui
Consulting or Advisory Role - BMSi; MSD Oncology
Speakers' Bureau - BMSi; Merck; MSD Oncology
Travel, Accommodations, Expenses - BMSi; Merck; MSD Oncology; Roche
 
William Nassib William
Employment - Grupo Oncoclinicas
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Janssen; Lilly; Merck; Novartis; Pfizer; Regeneron; Roche/Genentech; Sanofi/Aventis; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck; Pfizer; Roche
Speakers' Bureau - Boehringer Ingelheim
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); OSI Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck; Roche/Genentech
 
Nabil F. Saba
Honoraria - American Journal OF Managed Care; AstraZeneca; Coherus Biosciences; Eisai; EMD Serono; Exelixis; Fulgent Pharma; GlaxoSmithKline; Inovio Pharmaceuticals; Merck; Novartis; Taiho Pharmaceutical; TOSK; vaccinex
Consulting or Advisory Role - Akeso Biopharma; Fulgent Pharma; GlaxoSmithKline; Seagen
Research Funding - Bristol-Myers Squibb; Exelixis
Patents, Royalties, Other Intellectual Property - Springer textbook Royalty; Uptodate chapter writing and editing
Travel, Accommodations, Expenses - Merck
 
Christine H. Chung
Consulting or Advisory Role - AVEO; Exelixis; Fulgent Pharma; Genmab; Seagen
 
Ariel E. Birnbaum
No Relationships to Disclose
 
Dan Paul Zandberg
Consulting or Advisory Role - Bicara Therapeutics; Blueprint Medicines; InhibRx; Macrogenics; Merck; Prelude Therapeutics; Seagen
Research Funding - Aduro Biotech (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); EMD Serono (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Macrogenics (Inst); Merck (Inst); Novasenta (Inst)
 
Allison Wehr
Employment - Pfizer; Seagen
Stock and Other Ownership Interests - Pfizer; Seagen
 
Leonardo Viana Nicacio
Employment - Pfizer; Seagen
Stock and Other Ownership Interests - Florence Healthcare; Pfizer; Seagen
Honoraria - Pfizer; Seagen
Travel, Accommodations, Expenses - Pfizer; Seagen
 
Ibrahima Soumaoro
Employment - Genmab
Stock and Other Ownership Interests - Bristol-Myers Squibb; Genmab
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genmab
 
Anne-Sophie Carret
Employment - Pfizer; Seagen
Stock and Other Ownership Interests - Pfizer; Seagen
Honoraria - Seagen
Travel, Accommodations, Expenses - Pfizer; Seagen
 
Tanguy Y. Seiwert
Honoraria - Merck
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Bayer; BioNTech SE; BostonGene; CUE Biopharma; Eisai; Exelixis; Innate Pharma; IO Biotech; ITeos Therapeutics; Merck; Nanobiotix; Regeneron; Sanofi; Seattle Genetics/Astellas; Surface Oncology; VIR Biotechnology
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cue Biopharma (Inst); Dracen (Inst); Genentech/Roche (Inst); Merck (Inst); Nanobiotix (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - BostonGene; Coherus Biosciences; Nanobiotix